We claim:

1. A method of treating a disease or condition mediated by modulation of Nav1.7, comprising administering (5*R*)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-L-prolinamide, or a pharmaceutically acceptable salt thereof, to a subject not receiving treatment with a UGT inhibitor.

2. The method of claim 1, wherein the disease or condition is associated with a defect or dysfunction of Nav1.7.

3. The method of claim 1 or 2, wherein the UGT inhibitor is selected from canagliflozin, dapagliflozin, mefenamic acid, probenecid, diclofenac, quinidine, fluconazole, and valproic acid.

4. The method of any one of claims 1-3, wherein the method further comprises

a) determining whether the subject is receiving treatment with a UGT inhibitor and

b) if the subject is receiving treatment with a UGT inhibitor, discontinuing treatment with the UGT inhibitor prior to commencing treatment with (5*R*)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-L-prolinamide, or a pharmaceutically acceptable salt thereof, and/or

c) if the subject is not receiving treatment with a UGT inhibitor, instructing the subject not to commence treatment with a UGT inhibitor while receiving treatment with (5*R*)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-L-prolinamide, or a pharmaceutically acceptable salt thereof.

5. The method of any one of claims 1-4, wherein the method comprises instructing the subject to discontinue treatment with the UGT inhibitor before commencing treatment with (5*R*)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-L-prolinamide, or a pharmaceutically acceptable salt thereof.

6. The method of any one of claims 1-5, wherein discontinuing treatment with the UGT inhibitor comprises discontinuing treatment with the UGT inhibitor at least three weeks before

commencing treatment with (5*R*)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-L-prolinamide, or a pharmaceutically acceptable salt thereof.

7. The method of any one of claims 1-6, wherein administering (5*R*)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-L-prolinamide, or a pharmaceutically acceptable salt thereof, comprises administering (5*R*)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-L-prolinamide, or a pharmaceutically acceptable salt thereof, one time per day (OID).

8. The method of any one of claims 1-6, wherein administering (5*R*)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-L-prolinamide, or a pharmaceutically acceptable salt thereof, comprises administering (5*R*)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-L-prolinamide, or a pharmaceutically acceptable salt thereof, two times per day (BID).

9. The method of any one of claims 1-6, wherein administering (5*R*)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-L-prolinamide, or a pharmaceutically acceptable salt thereof, comprises administering (5*R*)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-L-prolinamide, or a pharmaceutically acceptable salt thereof, three times per day (TID).

10. The method of any one of claims 1-9, wherein administering (5*R*)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-L-prolinamide, or a pharmaceutically acceptable salt thereof, comprises administering (5*R*)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-L-prolinamide, or a pharmaceutically acceptable salt thereof, at a dosage of about 150 mg to about 400 mg.

11. The method of any one of claims 1-10, wherein the subject is female.

12. The method of any one of claims 1-10, wherein the subject is male.

13. The method of any one of claims 1-12, wherein administering (5*R*)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-L-prolinamide, or a pharmaceutically acceptable salt thereof, comprises administering (5*R*)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-L-prolinamide, or a pharmaceutically acceptable salt thereof, at a dosage of about 200 mg two times per day (BID).

14. The method of any one of claims 1-12, wherein administering (5*R*)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-L-prolinamide, or a pharmaceutically acceptable salt thereof, comprises administering (5*R*)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-L-prolinamide, or a pharmaceutically acceptable salt thereof, at a dosage of about 150 mg three times per day (TID).

15. The method of any one of claims 1-12, wherein administering (5*R*)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-L-prolinamide, a pharmaceutically acceptable salt thereof, comprises administering (5*R*)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-L-prolinamide, or a pharmaceutically acceptable salt thereof, at a dosage of about 250 mg three times per day (TID).

16. The method of claim 15, wherein the subject was not previously treated with (5*R*)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-L-prolinamide, or a pharmaceutically acceptable salt thereof.

17. The method of claim 15, wherein the subject had previously been treated with a 150 mg dosage of (5*R*)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-L-prolinamide, or a pharmaceutically acceptable salt thereof; *e.g.*, wherein the subject was identified as a non-responder to treatment with a dosage of about 150 mg of (5*R*)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-L-prolinamide, or a pharmaceutically acceptable salt thereof.

18. The method of any one of claims 1-12, wherein administering (5*R*)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-L-prolinamide, or a pharmaceutically acceptable salt thereof, comprises administering (5*R*)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-L-prolinamide, or a pharmaceutically acceptable salt thereof, at a dosage of about 300 mg to about 400 mg two times per day (BID).

19. The method of claim 18, wherein the dosage is about 300 mg BID.

20. The method of claim 19, wherein the subject is a female subject.

21. The method of claim 19 or 20, wherein the method further comprises administering (5*R*)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-L-prolinamide, or a pharmaceutically acceptable salt

thereof, at a dosage of about 400 mg BID for an initial period of time prior to administering (5*R*)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-L-prolinamide, or a pharmaceutically acceptable salt thereof, at a dosage of about 300 mg BID.

22. The method of claim 21, wherein the initial period of time is about one week.

23. The method of claim 18, wherein the dosage is about 400 mg BID.

24. The method of claim 23, wherein the subject is a male subject.

25. The method of any one of claims 1-24, wherein administering (5*R*)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-L-prolinamide, or a pharmaceutically acceptable salt thereof, comprises administering (5*R*)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-L-prolinamide, or a pharmaceutically acceptable salt thereof, orally.

26. The method of any one of claims 1-25, comprising wherein administering (5*R*)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-L-prolinamide, or a pharmaceutically acceptable salt thereof, comprises administering (5*R*)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-L-prolinamide, or a pharmaceutically acceptable salt thereof, in combination with one or more therapeutically effective medicaments.

27. The method of any one of claims 1-26, wherein the disease or condition is pain.

28. The method of claim 27, wherein the pain is neuropathic pain.

29. The method of claim 28, wherein the neuropathic pain is selected from diabetic neuropathy; sciatica; non-specific lower back pain; painful lumbosacral radiculopathy; multiple sclerosis pain; fibromyalgia; HIV-related neuropathy; post-herpetic neuralgia; trigeminal neuralgia; and pain resulting from physical trauma, amputation, cancer, toxins or chronic inflammatory conditions.

30. The method of claim 28, wherein the neuropathic pain is selected from trigeminal neuralgia, painful lumbosacral radiculopathy, erythromelalgia, and small fibre neuropathy.

31. The method of claim 28, wherein the neuropathic pain is trigeminal neuralgia.

32. The method of claim 31, comprising administering (5*R*)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-L-prolinamide, or a pharmaceutically acceptable salt thereof, to the subject at a dosage of about 250 mg three times per day (TID).

33. The method of claim 28, wherein the neuropathic pain is painful lumbosacral radiculopathy.

34. The method of claim 33, comprising administering (5*R*)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-L-prolinamide, or a pharmaceutically acceptable salt thereof, to the subject at a dosage of about 200 mg two times per day (BID).

35. The method of any one of claims 1-34, wherein the (5*R*)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-L-prolinamide, or a pharmaceutically acceptable salt thereof, is administered as a pharmaceutical composition comprising one or more pharmaceutically acceptable carrier(s), diluent(s), and/or excipient(s).

36. The method of any one of claims 1-35, wherein the (5*R*)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-L-prolinamide is present as a hydrochloride salt.

37. A method of treating a disease or condition mediated by modulation of Nav1.7, comprising administering (5*R*)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-L-prolinamide, or a pharmaceutically acceptable salt thereof, to a subject receiving treatment with a UGT inhibitor.

38. The method of claim 37, wherein the disease or condition is associated with a defect or dysfunction of Nav1.7.

39. The method of claim 37 or 38, wherein the UGT inhibitor is selected from canagliflozin, dapagliflozin, mefenamic acid, probenecid, diclofenac, quinidine, fluconazole, and valproic acid.

40. The method of any one of claims 37-39, wherein administering (5*R*)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-L-prolinamide, or a pharmaceutically acceptable salt thereof, comprises administering (5*R*)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-L-prolinamide, or a pharmaceutically acceptable salt thereof, one time per day (OID).

41. The method of any one of claims 37-39, wherein administering (5*R*)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-L-prolinamide, or a pharmaceutically acceptable salt thereof, comprises administering (5*R*)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-L-prolinamide, or a pharmaceutically acceptable salt thereof, two times per day (BID).

42. The method of any one of claims 37-39, wherein administering (5*R*)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-L-prolinamide, or a pharmaceutically acceptable salt thereof, comprises administering (5*R*)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-L-prolinamide, or a pharmaceutically acceptable salt thereof, three times per day (TID).

43. The method of any one of claims 37-42, wherein administering (5*R*)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-L-prolinamide, or a pharmaceutically acceptable salt thereof, comprises administering (5*R*)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-L-prolinamide, or a pharmaceutically acceptable salt thereof, at a dosage at least 30% lower than a dosage for a subject not using a UGT inhibitor.

44. The method of any one of claims 37-42, wherein administering (5*R*)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-L-prolinamide, or a pharmaceutically acceptable salt thereof, comprises administering (5*R*)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-L-prolinamide, or a pharmaceutically acceptable salt thereof, at a dosage at least 50% lower than a dosage for a subject not using a UGT inhibitor.

45. The method of any one of claims 37-42, wherein administering (5*R*)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-L-prolinamide, or a pharmaceutically acceptable salt thereof,

comprises administering (5*R*)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-L-prolinamide, or a pharmaceutically acceptable salt thereof, at a dosage of about 50 mg to about 350 mg BID.

46. The method of claim 45, wherein the dosage is about 50 mg BID, about 100 mg BID, about 150 mg BID, about 200 mg BID, or about 350 mg BID.

47. The method of any one of claims 37-42, wherein administering (5*R*)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-L-prolinamide, or a pharmaceutically acceptable salt thereof, comprises administering (5*R*)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-L-prolinamide, or a pharmaceutically acceptable salt thereof, at a dosage of about 50 mg to about 250 mg TID.

48. The method of claim 47, wherein the dosage is about 50 mg TID, about 75 mg TID, about 100 mg TID, about 150 mg TID, or about 250 mg TID.

49. The method of any one of claims 37-48, wherein administering (5*R*)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-L-prolinamide, or a pharmaceutically acceptable salt thereof, comprises administering (5*R*)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-L-prolinamide, or a pharmaceutically acceptable salt thereof, orally.

50. The method of any one of claims 37-49, wherein administering (5*R*)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-L-prolinamide, or a pharmaceutically acceptable salt thereof, comprises administering (5*R*)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-L-prolinamide, or a pharmaceutically acceptable salt thereof, in combination with one or more therapeutically effective medicaments.

51. The method of any one of claims 37-50, wherein the disease or condition is pain.

52. The method of claim 51, wherein the pain is neuropathic pain.

53. The method of claim 52, wherein the neuropathic pain is selected from diabetic neuropathy; sciatica; non-specific lower back pain; painful lumbosacral radiculopathy; multiple sclerosis pain; fibromyalgia; HIV-related neuropathy; post-herpetic neuralgia; trigeminal

neuralgia; and pain resulting from physical trauma, amputation, cancer, toxins or chronic inflammatory conditions.

54. The method of claim 53, wherein the neuropathic pain is selected from trigeminal neuralgia, painful lumbosacral radiculopathy, erythromelalgia and small fibre neuropathy.

55. The method of claim 54, wherein the neuropathic pain is trigeminal neuralgia.

56. The method of claim 55, comprising administering (5*R*)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-L-prolinamide, or a pharmaceutically acceptable salt thereof, to the subject at a dosage of about 50 mg to about 250 mg TID.

57. The method of claim 56, wherein the dosage is about 50 mg TID, about 75 mg TID, about 100 mg TID, about 150 mg TID, or about 250 mg TID.

58. The method of claim 54, wherein the neuropathic pain is painful lumbosacral radiculopathy.

59. The method of claim 58, comprising administering (5*R*)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-L-prolinamide, or a pharmaceutically acceptable salt thereof, to the subject at a dosage of about 50 mg to about 350 mg BID.

60. The method of claim 59, wherein the dosage is about 50 mg BID, about 75 mg BID, about 100 mg BID, about 150 mg BID, about 200 mg BID, or about 350 mg BID.

61. The method of any one of claims 37-60, comprising administering (5*R*)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-L-prolinamide, or a pharmaceutically acceptable salt thereof as a pharmaceutical composition comprising one or more pharmaceutically acceptable one or more pharmaceutically acceptable carrier(s), diluent(s), and/or excipient(s).

62. The method of any one of claims 37-61, wherein the (5*R*)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-L-prolinamide is present as a hydrochloride salt.